Before joining DEINOVE, Sébastien Enault was in charge of the Business Development of Eligo Bioscience, a start-up hosted at the Institut Pasteur in Paris, which develops a new generation of ultra-targeted antibiotics. Préviously, Sébastien Enault has structured and managed the Business Development of MedinCell, a biopharmaceutical company specializing in long-acting drug delivery. In ten years, he has contributed to the rapid growth of the company, including the signing of partnerships and agreements with major pharmaceutical companies. Prior to his experience in the private sector, Sébastien conducted research in pharmacology in the fields of infectious diseases, oncology and neurology at the Faculty of Pharmacy in Marseille, then at Cancer Research UK, and at Harvard Medical School.
Sébastien Enault is an Engineer in Pharmacology & Biotechnologies (Polytechnic School of Nice Sophia-Antipolis, France), and graduated in Business Development from the CEGOS training program.